These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 36300090)

  • 1. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
    Tettero JM; Al-Badri WKW; Ngai LL; Bachas C; Breems DA; van Elssen CHMJ; Fischer T; Gjertsen BT; van Gorkom GNY; Gradowska P; Greuter MJE; Griskevicius L; Juliusson G; Maertens J; Manz MG; Pabst T; Passweg J; Porkka K; Löwenberg B; Ossenkoppele GJ; Janssen JJWM; Cloos J
    Front Oncol; 2022; 12():999822. PubMed ID: 36300090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia.
    Zheng Y; Pan L; Li J; Feng X; Li C; Zheng M; Mai H; Yang L; He Y; He X; Xu H; Wen H; Le S
    BMC Cancer; 2024 Jan; 24(1):46. PubMed ID: 38195455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.
    Ahmed S; Elsherif M; Yassin D; Elsharkawy N; Mohamed AS; Yasser N; Elnashar A; Hafez H; Kolb EA; Elhaddad A
    Front Oncol; 2024; 14():1340909. PubMed ID: 38720804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRD Tailored Therapy in AML: What We Have Learned So Far.
    Ngai LL; Kelder A; Janssen JJWM; Ossenkoppele GJ; Cloos J
    Front Oncol; 2020; 10():603636. PubMed ID: 33575214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia.
    Revoltar M; van der Linde R; Cromer D; Gatt PN; Smith S; Fernandez MA; Vaughan L; Blyth E; Curnow J; Tegg E; Brown DA; Sasson SC
    Pathology; 2024 Oct; 56(6):882-888. PubMed ID: 39025727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients.
    Tembhare PR; Narula G; Khanka T; Ghogale S; Chatterjee G; Patkar NV; Prasad M; Badrinath Y; Deshpande N; Gudapati P; Verma S; Sanyal M; Kunjachan F; Mangang G; Gujral S; Banavali S; Subramanian PG
    Front Oncol; 2020; 10():577. PubMed ID: 32391267
    [No Abstract]   [Full Text] [Related]  

  • 7. Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia.
    Vial JP; Lechevalier N; Lacombe F; Dumas PY; Bidet A; Leguay T; Vergez F; Pigneux A; Béné MC
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
    Daga S; Rosenberger A; Kashofer K; Heitzer E; Quehenberger F; Halbwedl I; Graf R; Krisper N; Prietl B; Höfler G; Reinisch A; Zebisch A; Sill H; Wölfler A
    Am J Hematol; 2020 Oct; 95(10):1148-1157. PubMed ID: 32602117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study.
    Ashouri K; Nittur V; Ginosyan AA; Hwang J; Adnani B; Chen D; Savitala-Damerla L; Schiff K; Chaudhary P; Kovach AE; Ladha A; Siddiqi I; Ali A; Woan K; Tam E; Yaghmour G
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):e59-e66.e2. PubMed ID: 38061959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going.
    Dix C; Lo TH; Clark G; Abadir E
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32503122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.
    Buccisano F; Palmieri R; Piciocchi A; Maurillo L; Del Principe MI; Paterno G; Soddu S; Cerretti R; De Angelis G; Mariotti B; Irno Consalvo MA; Conti C; Fraboni D; Divona M; Ottone T; Lavorgna S; Panetta P; Voso MT; Arcese W; Venditti A
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.
    Hanekamp D; Tettero JM; Ossenkoppele GJ; Kelder A; Cloos J; Schuurhuis GJ
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia.
    Shao J; Shah S; Ganguly S; Zu Y; He C; Li Z
    Clin Epigenetics; 2023 Aug; 15(1):134. PubMed ID: 37620919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions.
    Moritz J; Schwab A; Reinisch A; Zebisch A; Sill H; Wölfler A
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell immune landscape of measurable residual disease in acute myeloid leukemia.
    Mo X; Zhang W; Fu G; Chang Y; Zhang X; Xu L; Wang Y; Yan C; Shen M; Wei Q; Yan C; Huang X
    Sci China Life Sci; 2024 Jul; ():. PubMed ID: 39034351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
    Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
    medRxiv; 2023 Mar; ():. PubMed ID: 37034683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia.
    Jentzsch M; Schwind S; Bach E; Stasik S; Thiede C; Platzbecker U
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.
    Dillon LW; Higgins J; Nasif H; Othus M; Beppu L; Smith TH; Schmidt E; Valentine Iii CC; Salk JJ; Wood BL; Erba HP; Radich JP; Hourigan CS
    Haematologica; 2024 Feb; 109(2):401-410. PubMed ID: 37534515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
    Tettero JM; Heidinga ME; Mocking TR; Fransen G; Kelder A; Scholten WJ; Snel AN; Ngai LL; Bachas C; van de Loosdrecht AA; Ossenkoppele GJ; de Leeuw DC; Cloos J; Janssen JJWM
    Leukemia; 2024 Mar; 38(3):630-639. PubMed ID: 38272991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRD-directed and risk-adapted individualized stratified treatment of AML.
    Zhao Y; Guo H; Chang Y
    Chin J Cancer Res; 2023 Oct; 35(5):451-469. PubMed ID: 37969959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.